NCT05491902 is a clinical trial of [C11] Leucine PET scan in Alzheimer Disease, sponsored by University of Manchester.

Who is sponsoring NCT05491902?

NCT05491902 is sponsored by University of Manchester.

What drugs are being tested in NCT05491902?

Interventions in NCT05491902: [C11] Leucine PET scan, [18F] Flutemetamol PET scan, MRI scan.

What condition does NCT05491902 study?

NCT05491902 studies Alzheimer Disease.

Is NCT05491902 still recruiting?

NCT05491902 is currently terminated. Last updated 8 August 2022.

Last reviewed 2022-08-08 · How we verify

NCT05491902

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot PET Study of Regional Cerebral Protein Synthesis in Alzheimer's

Terminated Last updated 8 August 2022

What this trial tests

trial testing [C11] Leucine PET scan in Alzheimer Disease in 10 participants. Terminated before completion.

Timeline

9 October 2017

Primary endpoint
15 October 2020

15 October 2020

Quick facts

Lead sponsor	University of Manchester
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	10
Start date	9 October 2017
Primary completion	15 October 2020
Estimated completion	15 October 2020
Sites	2 locations across United Kingdom

Drugs / interventions tested

[C11] Leucine PET scan
[18F] Flutemetamol PET scan
MRI scan

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

University of Manchester

Who can join

18 and older, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Measuring the rate of cerebral protein synthesis (rCPS) may enable us to better-understand the progression of Alzheimer's Disease (AD). This study is using a new method of measuring rCPS non-invasively, and to offer new approaches to the assessment of new therapeutic strategies in clinical trials. Previous studies have established the utility of \[11C\]-Leucine PET to assess the rCPS. This study will use \[11C\]- Leucine PET to measure rCPS in AD patients versus age-matched and young healthy subjects to determine whether a measurable difference exists. The study will involve participants receiving up to two PET scans, a structural MRI scan. The PET scanning procedures will involve some withdrawal of blood samples. The ultimate goal of this proposal is to indicate new routes for treatment of AD.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Quantitative Imaging of Regional Cerebral Protein Synthesis in Clinical Alzheimer's Disease by [<sup>11</sup>C]Leucine PET.
Herholz K, McMahon A, Thompson JC, Jones M, et al · · 2024 · PMID 39567463 · DOI 10.1007/s11307-024-01965-3

Verify or expand the search:

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other University of Manchester trials

Trials by the same sponsor.

NCT07506096 — Using IF-THEN Plans to Support Healthcare Professionals in Raising Patient Safety Concerns · NA · not yet recruiting
NCT07084090 — Using IF-THEN Plans to Support Patients in Raising Safety Concerns About Their Care · NA · not yet recruiting
NCT07494760 — A Feasibility Randomised Control Trial to Evaluate Early Perinatal Bereavement Counselling for Parents Who Have Experien · NA · not yet recruiting
NCT07372885 — GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia · Phase 1, PHASE2 · not yet recruiting
NCT07381894 — Multicentre Hypertrophic Cardiomyopathy Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05491902 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Manchester
Last refreshed: 8 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05491902.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing